Related Experiment Videos

Treatment options in hormone resistant prostate cancer

P H M De Mulder¹, J A Schalken, C N Sternberg

¹Department of Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands.

Annals of Oncology : Official Journal of the European Society for Medical Oncology

|October 29, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

ESMO open·2026

Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.

Urologic oncology·2025

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.

ESMO open·2023

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

ESMO open·2022

See all related articles